Table 1. Sensitivities of the parental and dual-resistant KCL-22 cells and K562 cells and clones to imatinib, dasatinib, GDC-0941 and GDC-0973.
| Cell line | Imatinib (GI50, μm) | Dasatinib (GI50, μm) | GDC-0941 (GI50, μm) | GDC-0973 (GI50, μm) |
|---|---|---|---|---|
| K562 parental | 0.3 | <0.001 | 2 | 0.88 |
| Dual-resistant cells | >10 | >10 | 0.02 | 1.1 |
| Clone 4 | >10 | >10 | 0.22 | 2 |
| Clone 11 | >10 | >10 | 0.36 | 8 |
| Clone 12 | >10 | >10 | 0.29 | 5 |
| Clone 13 | >10 | >10 | 0.47 | 3.5 |
| Clone 17 | >10 | >10 | 0.1 | 2.3 |
| Clone 20 | >10 | >10 | 0.17 | 0.55 |
| KCL-22 parental | 0.28 | <0.001 | 1.5 | 1 |
| KCL-22 resistant | >10 | >10 | 1.5 | 3.5 |
The cells were treated with 0–10 μm of the indicated inhibitors for 72 h, followed by measurement of cell viability by CellTiter-Glo assay. The cell viability after 72 h was corrected relative to time zero (time of treatment). GI50 values to all single agents are shown.